Next Article in Journal / Special Issue
The Multifactorial Etiopathogeneses Interplay of Inflammatory Bowel Disease: An Overview
Previous Article in Journal / Special Issue
Regulation of Antimicrobial Pathways by Endogenous Heat Shock Proteins in Gastrointestinal Disorders
Open AccessReview

CCR6–CCL20 Axis in IBD: What Have We Learnt in the Last 20 Years?

School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston 7248, Tasmania, Australia
*
Author to whom correspondence should be addressed.
Gastrointest. Disord. 2019, 1(1), 57-74; https://doi.org/10.3390/gidisord1010006
Received: 21 August 2018 / Revised: 23 September 2018 / Accepted: 12 October 2018 / Published: 15 October 2018
CC chemokine receptor 6 (CCR6) and its specific partner CC chemokine ligand 20 (CCL20) are known to play a pivotal role in intestinal inflammation. CCR6-associated inflammatory bowel disease (IBD) is already at the forefront of experimental inflammatory disease models, being the subject of numerous analytical studies. IBD is associated with two sub phenotypes, Crohn’s disease (CD) and ulcerative colitis (UC). Both these disease entities produce potent immune dysregulation followed by intense tissue damage within the gut mucosal system, initiating symptoms that are severely debilitating. Multiple causative factors are said to be responsible for IBD, but direct immune dysfunction is kindled by overplay of innate and adaptive immune responses produced against the luminal contents through the weakened or leaky gut epithelial barrier. Once immune homeostasis is not achieved by endogenous protective mechanisms, the self-assertive adaptive immunity mobilizes its various T and B cell cohorts, initializing their immune mechanisms by deploying the immune cells towards the site of infection. CCR6 and its unique solitary ligand CCL20 are small protein molecules that are abundantly expressed by T and B lymphocytes and act as chemotactic immune-modulatory envoys that help in the deployment of the effector lymphocyte arm of the immune system and produce two directly opposing outcomes in IBD. This dichotomous immunity consists of either immune tolerance or inflammation which then develops into a chronic state, remaining unresponsive to inherent immunity or targeted clinical therapy. In this review, we have identified large numbers of experimental studies that have employed both mouse models and clinical subjects spanning a period of nearly two decades and we have clustered these into 13 different groups. This review will provide greater understanding of the CCR6–CCL20 axis in IBD and identify gaps in the literature that can be filled in the future. View Full-Text
Keywords: inflammatory bowel disease; CCR6; CCL20; T helper lymphocytes; regulatory T cells; dendritic cells; TH17/Treg balance inflammatory bowel disease; CCR6; CCL20; T helper lymphocytes; regulatory T cells; dendritic cells; TH17/Treg balance
Show Figures

Figure 1

MDPI and ACS Style

Ranasinghe, R.; Eri, R. CCR6–CCL20 Axis in IBD: What Have We Learnt in the Last 20 Years? Gastrointest. Disord. 2019, 1, 57-74.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Back to TopTop